A carregar...
Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions
An understanding of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways has greatly changed the way metastatic renal cell carcinoma (RCC) is treated. Based on available phase III randomized trials, anti-VEGF agents such as sunitinib, sorafenib, bevacizumab-bas...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3126007/ https://ncbi.nlm.nih.gov/pubmed/21789125 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834009352498 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|